Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Awaits FDA Action On Aclasta After “Approvable” Letter For Paget’s Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis is waiting to hear back from FDA on the status of zoledronic acid for the treatment of Paget's disease of the bone after responding to an "approvable" letter from the agency

You may also be interested in...

Novartis Foresees Aclasta Approval By Year-End Despite Second "Approvable" Letter

FDA is seeking additional information from ongoing osteoporosis trials of the zoledronic acid for treatment of Paget's disease.

US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot

ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts